Tuesday | Wednesday | Thursday | Friday

FRIDAY, DECEMBER 10, 2021
All times are CENTRAL Time
   
7:00 am - 8:30 am  CT POSTER SESSION 5 - Hall 1
SPOTLIGHT POSTER DISCUSSION SESSIONS
  Spotlight Poster Discussion 13 - Novel Therapeutic Approaches in HER2 Negative Breast Cancer - Stars at Night Ballroom 1&2
 

Chair: Sara M. Tolaney, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Going beyond just endocrine therapy: The path ahead
Mafalda Oliveira, MD, PhD
Vall d'Hebron Institute of Oncology
Barcelona, Spain

Novel strategies for endocrine therapy: Can we do better?
Heather A. Parsons, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

 

Spotlight Poster Discussion 14 - Clinical Translational Updates in Invasive Lobular Carcinoma - Stars at Night Ballroom 3&4

 

Chair: TBD

Rachel C. Jankowitz, MD
Penn Medicine
Philadelphia. PA

Christine Desmedt, PhD
Katholieke Universiteit Leuven
Leuven, Belgium

  Spotlight Poster Discussion 15 - Defining Molecular Markers of Endocrine Resistance in Clinic - Hall 4A
 

Chair: Lajos Pusztai, MD, DPhil
Yale University School of Medicine
New Haven, CT

Komal Jhaveri, MD FACP
Memorial Sloan Kettering Cancer Center
New York, NY

Reva Basho, MD
Cedars-Sinai Cancer
Los Angeles, CA

8:45 am - 11:15 am CT

GENERAL SESSION 4 - Hall 3

8:45 am  GS4-01. Impact of race and ethnicity on incidence and severity of breast cancer related lymphedema after axillary lymph node dissection: Results of a prospective screening study
Barrio AV, Montagna G, Sevilimedu V, Gomez EA, Mehrara B, Morrow M. Memorial Sloan Kettering Cancer Center, New York, NY.

9:00 am 

GS4-02. Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial
Kyalwazi B, Yau C, Olopade O, A. Chien J, Wallace A, Forero-Torres A, Pusztai L, Ellis E, Albain K, Blaes A, Haley B, Boughey J, Elias A, Clark A, Isaacs C, Nanda R, Han H, Yung R, Tripathy D, Edmiston K, Viscusi R, Northfelt D, Khan Q, Sanil A, Berry S, Asare S, Wilson A, Hirst G, Hylton N, Melisko M, Perlmutter J, Rugo H, Symmans F, van ‘t Veer L, Berry D, Esserman L. University of Chicago Pritzker School of Medicine, Chicago, IL; University of California San Francisco, San Francisco, CA; University of Chicago, Chicago, IL; University of California San Diego, San Diego, CA; University of Alabama at Birmingham, Birmingham, AL; University of Texas MD Anderson Cancer Center, Houston, TX; Swedish Cancer Institute, Seattle, WA; Loyola University Chicago Stritch School of Medicine, Chicago, IL; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; Mayo Clinic Rochester, Rochester, MN; University of Colorado, Denver, CO; University of Pennsylvania, Philadelphia, PA; Georgetown, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Washington, Seattle, WA; University of Southern California, Los Angeles, CA; Inova Health System, Falls Church, VA; University of Arizona, Phoenix, AZ; Mayo Clinic Scottsdale, Scottsdale, AZ; University of Kansas, Kansas City, KS; Berry Consultants, LLC, Austin, TX; Quantum Leap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Harbor, MI.


9:15 am 

GS4-03. Patient-reported outcomes (PROs) for the intergroup sentinel mamma study (INSEMA, GBG75, ABCSG43): Persistent impact of axillary surgery on arm and breast symptoms in early breast cancer
Gerber B, Stachs A, Veselinovic K, Polata S, Müller T, Kühn T, Heil J, Ataseven B, Reitsamer R, Hildebrandt G, Knauer M, Golatta M, Stefek A, Zahm D-M, Thill M, Nekljudova V, Krug D, Seither F, Loibl S, Reimer T. Department of Obstetrics and Gynecology, University of Rostock, Rostock, Germany; Department of Obstetrics and Gynecology, University of Ulm, Ulm, Germany; Breast Center, Evangelisches Waldkrankenhaus Spandau, Berlin, Germany; Women’s Hospital, Klinikum Hanau GmbH, Hanau, Germany; Women’s Hospital, Klinikum Esslingen, Esslingen, Germany; Department of Obstetrics and Gynecology, Universitäsklinikum Heidelberg, Heidelberg, Germany; Kliniken Essen-Mitte, Essen, Germany; Breast Center, Gemeinnützige Salzburger Landeskliniken Betriebsgesellschaft, Salzburg, Austria; Department of Radiotherapy, University of Rostock, Rostock, Germany; Brustzentrum Ost, St. Gallen, Switzerland; Department of Obstetrics and Gynecology, Universitätsklinikum Heidelberg, Heidelberg, Germany; Women’s Hospital, Johanniter-Krankenhaus Stendal, Stendal, Germany; Breast Center, SRH Waldklinikum Gera, Gera, Germany; Breast Center, AGAPLESION Markus Krankenhaus, Frankfurt, Germany; German Breast Group, Neu-Isenburg, Germany; Universitätsklinikum Schleswig-Holstein, Kiel, Germany.


9:30 am 

GS4-04. Discussant
Lisa A. Newman, MD, MPH
New York-Presbyterian/Weill Cornell Medical Center
New York, NY


9:45 am  GS4-05. Preservation of axillary lymph nodes compared to complete dissection in T1-T2 breast cancer patients presenting 1-2 metastatic sentinel lymph nodes. A multicenter randomized clinical trial. Sinodar One
Gentile D, Gatzemeier W, Barbieri E, Sagona A, Bottini A, Errico V, Testori A, Scorsetti M, Canavese G, Tinterri C. Humanitas Research Hospital, Milano, Italy.

10:00 am  GS4-06 Estimation of breast cancer over diagnosis in a US breast screening cohort
Ryser MD, Lange J, Inoue L, O'Meara ES, Gard C, Miglioretti DL, Bulliard J-L, Brouwer AF, Hwang ES, Etzioni RB. Duke University, Durham, NC; Oregon Health & Science University, Portland, OR; University of Washington, Seattle, WA; Kaiser Permanente Washington Health Research Institute, Seattle, WA; New Mexico State University, Las Cruces, NM; University of California, Davis, Davis, CA; University of Lausanne, Lausanne, Switzerland; University of Michigan, Ann Arbor, MI;9Fred Hutchinson Cancer Research Center, Seattle, WA.
   
10:15 am 

GS4-07. The Breast PreCancer Atlas DCIS genomic signatures define biology and correlate with clinical outcomes: An analysis of TBCRC 038 and RAHBT cohorts
Strand SH, Rivero-Gutiérrez B, Houlahan KE, Seoane JA, King LM, Risom T, Simpson L, Vennam S, Khan A, Hardman T, Harmon BE, Couch FJ, Gallagher K, Kilgore M, Wei S, DeMichele A, King T, McAuliffe PF, Nangia J, Lee J, Tseng J, Storniolo AM, Thompson A, Gupta G, Burns R, Veis DJ, DeSchryver K, Zhu C, Matusiak M, Wang J, Zhu SX, Tappenden J, Yi Ding D, Zhang D, Luo J, Jiang S, Varma S, Straub C, Srivastava S, Curtis C, Tibshirani R, Angelo RM, Hall A, Owzar K, Polyak K, Maley C, Marks JR, Colditz GA, Hwang ES, West RB. Stanford, Stanford, CA; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Duke, Durham, NC; Montefiore, Bronx, NY; Mayo Clinic, Rochester, MN; University of North Carolina at Chapel Hill, Chapel Hill, NC; University of Washington, Seattle, WA; University of Alabama at Birmingham, Birmingham, AL; University of Pennsylvania, Philadelphia, PA; Dana-Farber Cancer Institute, Boston, MA; University of Pittsburgh, Pittsburgh, PA; Baylor College of Medicine, Houston, TX; MD Anderson Cancer Center, Houston, TX; University of Chicago, Chicago, IL; Indiana University, Indianapolis, IN; The EMMES Corporation, Rockville, MD; Washington University, St. Louis, MO; ASU, Tempe, AZ.


10:30 am  GS4-08.Comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating therapy resistance
Safonov A, Bandlamudi C, Tallón de Lara P, Ferraro E, Derakhshan F, Will M, Donoghue M, Selenica P, Drago J, Rosen E, dos Anjos C, Walsh E, Comen EA, Ahmed M, Acevedo B, Zehir A, Berger MF, Solit D, Norton L, Shen R, Stadler Z, Powell S, Reis-Filho JS, Chandarlapaty S, Robson M, Razavi P. Memorial Sloan Kettering Cancer Center, New York, NY.

10:45 am 

GS4-09. Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer
Ganz PA, Bandos H, Spanic T, Friedman S, Müller V, Kümmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Dueñas E-M, Armstrong A, Im S-A, Song C, Zheng H, Sarosiek T, Sharma P, Rossi G, Rastogi P, Fielding A, Gelber RD, Campbell C, Garber JE, Geyer Jr CE, Tutt ANJ, On behalf of the OlympiA Trial Steering Committee and Investigators. NSABP/NRG Oncology, and UCLA Jonsson Comprehensive Cancer Center, and UCLA Fielding School of Public Health, Los Angeles, PA; NSABP/NRG Oncology, and The University of Pittsburgh, Pgh, PA; Europa Donna, The European Breast Cancer Coalition, Milan, Italy; Facing Our Risk of Cancer Empowered (FORCE), Tampa, FL; University Medical Cener Hamburg-Eppendorf, Hamburg, Germany; Charité – Universitätsmedizin Berlin, Department of Gynecology with Breast Center Breast Unit, Kliniken Essen-Mitte, Berlin, Germany; UNICANCER Breast Group (UCBG), Institut Gustave Roussy, Villejuif, France; Institut Curie, Saint-Cloud, France; Japan Breast Research Group (JBCRG), and Kyoto University Hospital, Kyoto, Japan; Japan Breast Research Group (JBCRG), and St. Luke's International Hospital, Tokyo, Japan; GEICAM Spanish Breast Cancer Group, and The Consorcio Hospitalario Provincial de Castellón, Castellón, Spain; National Cancer Research Institute - Breast Cancer Clinical Studies Group (NCRI-BCSG), The Christie NHS Foundation Trust, and the University of Manchester, Manchester, United Kingdom; Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Fujian Medical University Union Hospital, Fujian, China; Cancer Center, West China Hospital, Sichuan University, Chengdu, China; LUXMED Onkologia, Warsaw, Poland; University of Kansas Medical Center, Westwood, KS; Breast International Group (BIG), Brussels, Belgium; NSABP/NRG Oncology, and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, and Magee-Womens Hospital, Pittsburgh, PA; AstraZeneca, Gaithersburg, MD; Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, Frontier Science Foundation, Boston, MA; Frontier Science (Scotland) Ltd, Kincraig, United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, Frontier Science Foundation, and Alliance for Clinical Trials in Oncology, Boston, MA; NRG Oncology, and Houston Methodist Cancer Center, Houston, TX; Breast International Group (BIG), and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer and The Breast Cancer Now Unit, Guy’s Hospital Cancer Centre, King's College London, London, United Kingdom.


11:00 am  GS4-10. Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial
Jhaveri K, Park H, Waisman J, Goldman JW, Guerrero-Zotano A, Boni V, Haley B, Mayer IA, Brufsky A, Yang ES, García-Sáenz JA, Bidard F-C, Crown J, Zhang B, Frazier A, Diala I, Eli LD, Barnett B, Wildiers H. Memorial Sloan Kettering Cancer Center, New York, NY; Washington University School of Medicine, St. Louis, MO; City of Hope Comprehensive Cancer Center, Duarte, CA; UCLA, Santa Monica, CA; Fundación Instituto Valenciano de Oncología, Valencia, Spain; START Madrid-CIOCC, Hospital Universitario, Madrid Sanchinarro, Madrid, Spain; UT Southwestern Medical Center, Dallas, TX; Vanderbilt University Medical Center / Vanderbilt-Ingram Cancer Center, Nashville, TN; Magee-Womens Hospital of UPMC, Pittsburgh, PA; University of Alabama at Birmingham, Birmingham, AL; Hospital Clínico San Carlos, Madrid, Spain; Institut Curie, St. Cloud, France; St. Vincent’s University Hospital, Dublin, Ireland; Puma Biotechnology Inc., Los Angeles, CA; University Hospitals Leuven, Leuven, Belgium.

11:15 am  BREAK
 
10:00 am - 5:00 pm CT EXHIBITS - Hall 2
11:30 am - 12:30 pm CT DEBATE - Hall 3

One Week of Whole Breast RT is the New Standard of Care
Moderator: Wendy Woodward, MD, PhD
UT MD Anderson Cancer Center
Houston, TX

Pro
Charlotte E. Coles, PhD
University of Cambridge
Cambridge, United Kingdom

Con
Julia White, MD
The Ohio State University
Columbus, OH

 

12:30 pm - 1:00 pm CT  AACR Outstanding Investigator Award for Breast Cancer Research supported by the Breast Cancer Research Foundation - Hall 3
Moving toward precision medicine for patients with breast cancer

Fabricé Andre, MD, PhD
Gustave Roussy
Villejuif, France
 
1:00 pm - 1:30 pm CT  BREAK 
1:30 pm - 2:00 pm CT

PLENARY LECTURE - Hall 3

  Triple Negative Breast Cancer - Pitfalls and Progress
Lisa A. Carey, MD, ScM, FASCO
University of North Carolina at Chapel Hill
Chapel Hill, NC
2:00 pm - 3:00 pm CT MINI SYMPOSIA
 

DNA Repair in Breast Cancer - Diagnosis and Treatment - Stars at Night Ballroom 1&2
Moderator: Simon N. Powell, MD, PhD, FRCP
Memorial Sloan Kettering Cancer Center
New York, NY

CRISPR screens to identify novel DNA repair defects synthetic lethal therapies
Daniel Durocher, PhD
Lunefeld-Tanenbaum Research Institute
Toronto, Canada

Genomics of DNA repair defects in breast cancer
Serena Nik-Zainal, PhD
University of Cambridge
Cambridge, United Kingdom

Targeting DNA damage response and HRD in breast cancer
Timothy A. Yap, MBBS, PhD, FRCP
UT MD Anderson Cancer Center
Houston, TX


The Evolution of Local Therapy in the Genomic Era - Hall 3
Moderator: Tari King, MD
Brigham and Women's Hospital
Boston, MA

Is less (or more) axillary surgery needed in the genomic era?
Monica Morrow, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Can genomic risk be used to tailor radiation therapy?
Philip Poortmans, PhD
Iridium Netwerk & University of Antwerp
Antwerp, Belgium

3:00 pm - 5:00 pm CT YEAR IN REVIEW - Hall 3
 

Moderator: Carlos L. Arteaga, MD
Harold C. Simmons Comprehensive Cancer Center
UT Southwestern
Dallas, TX

Basic science
Xiang Zhang, PhD
Baylor School of Medicine
Houston, TX

Translational research
Christina Curtis, PhD, MSc
Stanford Medicine
Stanford, CA

Early breast cancer
Foluso Olabisi Ademuyiwa, MD, MPH, MSCI
Washington University School of Medicine
Saint Louis, MO

Advanced breast cancer
Peter Schmid, MD, PhD
Bart's Cancer Institute Queen Mary University of London
London, United Kingdom 

5:00 pm - 7:00 pm CT View from the Trenches: What will You do on Monday Morning? - Stars at Night Ballroom 1&2
 

Moderator: Stephen Johnston, MBBS, ARCP, PhD
The Royal Marsden Hospital
London, United Kingdom

Co-Moderator: Alastair Thompson, BSc (Hons), MBChB, MD, FRCSEd FACS
Baylor College of Medicine
Houston, TX

Panel Members

Carlos H. Barrios, MD
Latin American Cooperative Oncology Group (LACOG)
Porto Alegre, Brazil

Thomas Braun, PhD
University of Michigan
Ann Arbor, MI

Javier Cortes, MD, PhD
International Breast Cancer Center
Barcelona, Spain

Erika Hamilton, MD
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, TN

Meena Moran, MD
Yale School of Medicine
New Haven, CT

Ann H. Partridge, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Jorge S. Reis-Filho, MD, MRCPath, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Ivis Febus-Sampayo
SHARE
New York, NY

Anna C. Weiss, MD
Brigham and Women's Hospital
Boston, MA

7:30 pm CT OPEN SATELLITE EVENT In person Symposia will be held at the San Antonio Marriott Rivercenter hotel
Molecular Imaging and Breast Cancer: Selecting and Evaluating Targeted Treatment presented by Society of Nuclear Medicine and Molecular Imaging (SNMMI)
  Register for this complimentary in person symposia or virtual event: http://www.snmmi.org/sabcs.    
     
     
Tuesday | Wednesday | Thursday | Friday